nodes	percent_of_prediction	percent_of_DWPC	metapath
Apixaban—CYP2J2—Cholecalciferol—psoriasis	0.264	0.313	CbGbCtD
Apixaban—CYP2C8—Tazarotene—psoriasis	0.0431	0.0512	CbGbCtD
Apixaban—CYP3A5—Beclomethasone—psoriasis	0.0417	0.0495	CbGbCtD
Apixaban—CYP1A2—Clobetasol propionate—psoriasis	0.041	0.0486	CbGbCtD
Apixaban—ABCG2—Mycophenolate mofetil—psoriasis	0.03	0.0356	CbGbCtD
Apixaban—ABCG2—Hydrocortisone—psoriasis	0.0241	0.0285	CbGbCtD
Apixaban—ABCG2—Cyclosporine—psoriasis	0.0227	0.027	CbGbCtD
Apixaban—CYP1A2—Methoxsalen—psoriasis	0.0215	0.0255	CbGbCtD
Apixaban—CYP2C8—Cholecalciferol—psoriasis	0.0184	0.0219	CbGbCtD
Apixaban—CYP3A5—Mycophenolate mofetil—psoriasis	0.0166	0.0197	CbGbCtD
Apixaban—CYP2C8—Mycophenolate mofetil—psoriasis	0.016	0.019	CbGbCtD
Apixaban—CYP2C19—Cholecalciferol—psoriasis	0.0154	0.0183	CbGbCtD
Apixaban—ABCG2—Dexamethasone—psoriasis	0.015	0.0178	CbGbCtD
Apixaban—CYP3A4—Calcitriol—psoriasis	0.0145	0.0172	CbGbCtD
Apixaban—CYP3A5—Hydrocortisone—psoriasis	0.0133	0.0158	CbGbCtD
Apixaban—CYP2C9—Cholecalciferol—psoriasis	0.0128	0.0152	CbGbCtD
Apixaban—CYP2C8—Hydrocortisone—psoriasis	0.0128	0.0152	CbGbCtD
Apixaban—CYP3A5—Cyclosporine—psoriasis	0.0126	0.0149	CbGbCtD
Apixaban—CYP2C8—Cyclosporine—psoriasis	0.0121	0.0144	CbGbCtD
Apixaban—ABCG2—Methotrexate—psoriasis	0.012	0.0143	CbGbCtD
Apixaban—CYP3A4—Methoxsalen—psoriasis	0.0113	0.0134	CbGbCtD
Apixaban—ABCB1—Mycophenolate mofetil—psoriasis	0.0108	0.0128	CbGbCtD
Apixaban—CYP2C19—Prednisone—psoriasis	0.0107	0.0127	CbGbCtD
Apixaban—CYP2C19—Cyclosporine—psoriasis	0.0102	0.012	CbGbCtD
Apixaban—ABCB1—Betamethasone—psoriasis	0.00927	0.011	CbGbCtD
Apixaban—ABCB1—Prednisolone—psoriasis	0.00915	0.0109	CbGbCtD
Apixaban—ABCB1—Hydrocortisone—psoriasis	0.00867	0.0103	CbGbCtD
Apixaban—ABCB1—Prednisone—psoriasis	0.00864	0.0103	CbGbCtD
Apixaban—CYP2C9—Cyclosporine—psoriasis	0.00844	0.01	CbGbCtD
Apixaban—CYP3A5—Dexamethasone—psoriasis	0.00829	0.00984	CbGbCtD
Apixaban—ABCB1—Cyclosporine—psoriasis	0.00819	0.00972	CbGbCtD
Apixaban—CYP2C8—Dexamethasone—psoriasis	0.00797	0.00946	CbGbCtD
Apixaban—CYP3A4—Cholecalciferol—psoriasis	0.00747	0.00886	CbGbCtD
Apixaban—CYP2C19—Dexamethasone—psoriasis	0.00668	0.00793	CbGbCtD
Apixaban—CYP3A4—Mycophenolate mofetil—psoriasis	0.00648	0.00769	CbGbCtD
Apixaban—CYP3A4—Triamcinolone—psoriasis	0.00648	0.00769	CbGbCtD
Apixaban—CYP2C9—Dexamethasone—psoriasis	0.00556	0.0066	CbGbCtD
Apixaban—CYP3A4—Betamethasone—psoriasis	0.00556	0.00659	CbGbCtD
Apixaban—CYP3A4—Prednisolone—psoriasis	0.00548	0.00651	CbGbCtD
Apixaban—ABCB1—Dexamethasone—psoriasis	0.00539	0.0064	CbGbCtD
Apixaban—CYP3A4—Hydrocortisone—psoriasis	0.0052	0.00617	CbGbCtD
Apixaban—CYP3A4—Prednisone—psoriasis	0.00518	0.00614	CbGbCtD
Apixaban—CYP3A4—Cyclosporine—psoriasis	0.00491	0.00582	CbGbCtD
Apixaban—ABCB1—Methotrexate—psoriasis	0.00433	0.00514	CbGbCtD
Apixaban—CYP2J2—Xenobiotics—CYP2S1—psoriasis	0.00429	0.1	CbGpPWpGaD
Apixaban—CYP3A4—Dexamethasone—psoriasis	0.00323	0.00384	CbGbCtD
Apixaban—CYP2J2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00178	0.0417	CbGpPWpGaD
Apixaban—CYP2J2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00176	0.0412	CbGpPWpGaD
Apixaban—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.00173	0.0405	CbGpPWpGaD
Apixaban—F10—Beta2 integrin cell surface interactions—ITGAL—psoriasis	0.00172	0.0402	CbGpPWpGaD
Apixaban—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00154	0.0361	CbGpPWpGaD
Apixaban—CYP2J2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00144	0.0338	CbGpPWpGaD
Apixaban—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00141	0.0329	CbGpPWpGaD
Apixaban—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00124	0.029	CbGpPWpGaD
Apixaban—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.00107	0.0251	CbGpPWpGaD
Apixaban—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000956	0.0224	CbGpPWpGaD
Apixaban—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000872	0.0204	CbGpPWpGaD
Apixaban—CYP2J2—Biological oxidations—CYP2S1—psoriasis	0.000767	0.018	CbGpPWpGaD
Apixaban—CYP2J2—Metapathway biotransformation—CYP2S1—psoriasis	0.000757	0.0177	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL22—psoriasis	0.000749	0.0175	CbGpPWpGaD
Apixaban—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000745	0.0174	CbGpPWpGaD
Apixaban—F10—Beta2 integrin cell surface interactions—ICAM1—psoriasis	0.00071	0.0166	CbGpPWpGaD
Apixaban—CYP2J2—Tryptophan metabolism—CAT—psoriasis	0.000662	0.0155	CbGpPWpGaD
Apixaban—F10—Hemostasis—SERPINB8—psoriasis	0.0006	0.0141	CbGpPWpGaD
Apixaban—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000575	0.0135	CbGpPWpGaD
Apixaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000513	0.012	CbGpPWpGaD
Apixaban—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000507	0.0119	CbGpPWpGaD
Apixaban—ABCG2—Iron uptake and transport—CP—psoriasis	0.000479	0.0112	CbGpPWpGaD
Apixaban—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000445	0.0104	CbGpPWpGaD
Apixaban—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000439	0.0103	CbGpPWpGaD
Apixaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000416	0.00975	CbGpPWpGaD
Apixaban—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000397	0.0093	CbGpPWpGaD
Apixaban—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000392	0.00918	CbGpPWpGaD
Apixaban—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000362	0.00848	CbGpPWpGaD
Apixaban—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000361	0.00845	CbGpPWpGaD
Apixaban—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000357	0.00837	CbGpPWpGaD
Apixaban—Ecchymosis—Betamethasone—psoriasis	0.000344	0.003	CcSEcCtD
Apixaban—Ecchymosis—Dexamethasone—psoriasis	0.000344	0.003	CcSEcCtD
Apixaban—Rash—Beclomethasone—psoriasis	0.000342	0.00298	CcSEcCtD
Apixaban—Dermatitis—Beclomethasone—psoriasis	0.000341	0.00297	CcSEcCtD
Apixaban—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.00034	0.00796	CbGpPWpGaD
Apixaban—Rash—Fluocinonide—psoriasis	0.000339	0.00295	CcSEcCtD
Apixaban—Dermatitis—Fluocinonide—psoriasis	0.000338	0.00295	CcSEcCtD
Apixaban—Angiopathy—Hydroxyurea—psoriasis	0.000337	0.00294	CcSEcCtD
Apixaban—Petechiae—Methotrexate—psoriasis	0.000337	0.00293	CcSEcCtD
Apixaban—Haematuria—Mycophenolic acid—psoriasis	0.00033	0.00288	CcSEcCtD
Apixaban—Breast disorder—Cyclosporine—psoriasis	0.000329	0.00286	CcSEcCtD
Apixaban—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.000329	0.00286	CcSEcCtD
Apixaban—Hepatobiliary disease—Mycophenolic acid—psoriasis	0.000328	0.00285	CcSEcCtD
Apixaban—Liver function test abnormal—Mycophenolate mofetil—psoriasis	0.000328	0.00285	CcSEcCtD
Apixaban—Epistaxis—Mycophenolic acid—psoriasis	0.000327	0.00285	CcSEcCtD
Apixaban—Skin disorder—Acitretin—psoriasis	0.000326	0.00284	CcSEcCtD
Apixaban—Nausea—Beclomethasone—psoriasis	0.000322	0.0028	CcSEcCtD
Apixaban—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000322	0.00754	CbGpPWpGaD
Apixaban—Aspartate aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000319	0.00278	CcSEcCtD
Apixaban—Diabetes mellitus—Dexamethasone—psoriasis	0.000317	0.00277	CcSEcCtD
Apixaban—Diabetes mellitus—Betamethasone—psoriasis	0.000317	0.00277	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000313	0.00273	CcSEcCtD
Apixaban—Haemoglobin—Mycophenolic acid—psoriasis	0.000313	0.00272	CcSEcCtD
Apixaban—Hypersensitivity—Methoxsalen—psoriasis	0.000312	0.00272	CcSEcCtD
Apixaban—Haemorrhage—Mycophenolic acid—psoriasis	0.000311	0.00271	CcSEcCtD
Apixaban—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00031	0.00726	CbGpPWpGaD
Apixaban—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000309	0.00725	CbGpPWpGaD
Apixaban—Urinary tract disorder—Mycophenolic acid—psoriasis	0.000307	0.00268	CcSEcCtD
Apixaban—Connective tissue disorder—Mycophenolic acid—psoriasis	0.000306	0.00266	CcSEcCtD
Apixaban—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000305	0.00715	CbGpPWpGaD
Apixaban—Urethral disorder—Mycophenolic acid—psoriasis	0.000305	0.00266	CcSEcCtD
Apixaban—Ecchymosis—Prednisone—psoriasis	0.0003	0.00261	CcSEcCtD
Apixaban—Anaemia—Hydroxyurea—psoriasis	0.000299	0.0026	CcSEcCtD
Apixaban—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000293	0.00687	CbGpPWpGaD
Apixaban—Eye disorder—Mycophenolic acid—psoriasis	0.000291	0.00253	CcSEcCtD
Apixaban—Gastrointestinal disorder—Acitretin—psoriasis	0.00029	0.00253	CcSEcCtD
Apixaban—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000289	0.00252	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000285	0.00248	CcSEcCtD
Apixaban—Angiopathy—Mycophenolic acid—psoriasis	0.000282	0.00246	CcSEcCtD
Apixaban—Mediastinal disorder—Mycophenolic acid—psoriasis	0.00028	0.00244	CcSEcCtD
Apixaban—Dizziness—Methoxsalen—psoriasis	0.00028	0.00244	CcSEcCtD
Apixaban—Hypersensitivity—Calcitriol—psoriasis	0.000278	0.00242	CcSEcCtD
Apixaban—Diabetes mellitus—Prednisone—psoriasis	0.000276	0.00241	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000273	0.00238	CcSEcCtD
Apixaban—Melaena—Methotrexate—psoriasis	0.00027	0.00236	CcSEcCtD
Apixaban—Haematuria—Cyclosporine—psoriasis	0.000267	0.00233	CcSEcCtD
Apixaban—Rash—Methoxsalen—psoriasis	0.000267	0.00233	CcSEcCtD
Apixaban—Dermatitis—Methoxsalen—psoriasis	0.000267	0.00233	CcSEcCtD
Apixaban—Hepatobiliary disease—Cyclosporine—psoriasis	0.000265	0.00231	CcSEcCtD
Apixaban—Epistaxis—Cyclosporine—psoriasis	0.000264	0.0023	CcSEcCtD
Apixaban—Haematuria—Mycophenolate mofetil—psoriasis	0.000261	0.00227	CcSEcCtD
Apixaban—Nervous system disorder—Hydroxyurea—psoriasis	0.000259	0.00225	CcSEcCtD
Apixaban—Hepatobiliary disease—Mycophenolate mofetil—psoriasis	0.000259	0.00225	CcSEcCtD
Apixaban—Thrombocytopenia—Hydroxyurea—psoriasis	0.000258	0.00225	CcSEcCtD
Apixaban—Epistaxis—Mycophenolate mofetil—psoriasis	0.000258	0.00225	CcSEcCtD
Apixaban—Skin disorder—Hydroxyurea—psoriasis	0.000256	0.00223	CcSEcCtD
Apixaban—Haemoglobin—Cyclosporine—psoriasis	0.000253	0.0022	CcSEcCtD
Apixaban—Nausea—Methoxsalen—psoriasis	0.000252	0.00219	CcSEcCtD
Apixaban—Haemorrhage—Cyclosporine—psoriasis	0.000252	0.00219	CcSEcCtD
Apixaban—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000251	0.00587	CbGpPWpGaD
Apixaban—Ecchymosis—Methotrexate—psoriasis	0.00025	0.00218	CcSEcCtD
Apixaban—Anaemia—Mycophenolic acid—psoriasis	0.00025	0.00218	CcSEcCtD
Apixaban—Urinary tract disorder—Cyclosporine—psoriasis	0.000248	0.00216	CcSEcCtD
Apixaban—Hypersensitivity—Acitretin—psoriasis	0.000248	0.00216	CcSEcCtD
Apixaban—Connective tissue disorder—Cyclosporine—psoriasis	0.000247	0.00215	CcSEcCtD
Apixaban—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000247	0.00215	CcSEcCtD
Apixaban—Haemoglobin—Mycophenolate mofetil—psoriasis	0.000247	0.00215	CcSEcCtD
Apixaban—Urethral disorder—Cyclosporine—psoriasis	0.000247	0.00215	CcSEcCtD
Apixaban—Haemorrhage—Mycophenolate mofetil—psoriasis	0.000245	0.00214	CcSEcCtD
Apixaban—Syncope—Mycophenolic acid—psoriasis	0.000243	0.00212	CcSEcCtD
Apixaban—Urinary tract disorder—Mycophenolate mofetil—psoriasis	0.000242	0.00211	CcSEcCtD
Apixaban—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000241	0.0021	CcSEcCtD
Apixaban—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000241	0.0021	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Prednisone—psoriasis	0.00024	0.0021	CcSEcCtD
Apixaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000239	0.00559	CbGpPWpGaD
Apixaban—Rash—Calcitriol—psoriasis	0.000238	0.00207	CcSEcCtD
Apixaban—Loss of consciousness—Mycophenolic acid—psoriasis	0.000238	0.00207	CcSEcCtD
Apixaban—Dermatitis—Calcitriol—psoriasis	0.000238	0.00207	CcSEcCtD
Apixaban—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000236	0.00552	CbGpPWpGaD
Apixaban—Diabetes mellitus—Methotrexate—psoriasis	0.000231	0.00201	CcSEcCtD
Apixaban—Haemoglobin—Prednisolone—psoriasis	0.00023	0.002	CcSEcCtD
Apixaban—Eye disorder—Mycophenolate mofetil—psoriasis	0.000229	0.002	CcSEcCtD
Apixaban—Haemorrhage—Prednisolone—psoriasis	0.000229	0.00199	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000229	0.00199	CcSEcCtD
Apixaban—Angiopathy—Cyclosporine—psoriasis	0.000228	0.00199	CcSEcCtD
Apixaban—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000228	0.00198	CcSEcCtD
Apixaban—Mediastinal disorder—Cyclosporine—psoriasis	0.000227	0.00198	CcSEcCtD
Apixaban—Haemoglobin—Hydrocortisone—psoriasis	0.000225	0.00196	CcSEcCtD
Apixaban—Nausea—Calcitriol—psoriasis	0.000224	0.00195	CcSEcCtD
Apixaban—Haemorrhage—Hydrocortisone—psoriasis	0.000224	0.00195	CcSEcCtD
Apixaban—Angiopathy—Mycophenolate mofetil—psoriasis	0.000223	0.00194	CcSEcCtD
Apixaban—Dizziness—Acitretin—psoriasis	0.000222	0.00194	CcSEcCtD
Apixaban—Dizziness—Fluocinolone Acetonide—psoriasis	0.000222	0.00193	CcSEcCtD
Apixaban—Epistaxis—Triamcinolone—psoriasis	0.000221	0.00193	CcSEcCtD
Apixaban—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000221	0.00193	CcSEcCtD
Apixaban—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000221	0.00518	CbGpPWpGaD
Apixaban—Connective tissue disorder—Hydrocortisone—psoriasis	0.00022	0.00191	CcSEcCtD
Apixaban—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000218	0.00511	CbGpPWpGaD
Apixaban—Shock—Mycophenolic acid—psoriasis	0.000217	0.00189	CcSEcCtD
Apixaban—Nervous system disorder—Mycophenolic acid—psoriasis	0.000217	0.00189	CcSEcCtD
Apixaban—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000216	0.00188	CcSEcCtD
Apixaban—Skin disorder—Mycophenolic acid—psoriasis	0.000215	0.00187	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Prednisone—psoriasis	0.000212	0.00185	CcSEcCtD
Apixaban—Rash—Acitretin—psoriasis	0.000212	0.00185	CcSEcCtD
Apixaban—Dermatitis—Acitretin—psoriasis	0.000212	0.00184	CcSEcCtD
Apixaban—Haemoglobin—Triamcinolone—psoriasis	0.000212	0.00184	CcSEcCtD
Apixaban—Rash—Fluocinolone Acetonide—psoriasis	0.000211	0.00184	CcSEcCtD
Apixaban—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000211	0.00184	CcSEcCtD
Apixaban—Haemorrhage—Triamcinolone—psoriasis	0.000211	0.00183	CcSEcCtD
Apixaban—Eye disorder—Hydrocortisone—psoriasis	0.000209	0.00182	CcSEcCtD
Apixaban—Hypotension—Mycophenolic acid—psoriasis	0.000206	0.0018	CcSEcCtD
Apixaban—Anaemia—Cyclosporine—psoriasis	0.000202	0.00176	CcSEcCtD
Apixaban—Immune system disorder—Hydrocortisone—psoriasis	0.000202	0.00176	CcSEcCtD
Apixaban—Nausea—Acitretin—psoriasis	0.0002	0.00174	CcSEcCtD
Apixaban—Nausea—Fluocinolone Acetonide—psoriasis	0.000199	0.00173	CcSEcCtD
Apixaban—Anaemia—Mycophenolate mofetil—psoriasis	0.000197	0.00172	CcSEcCtD
Apixaban—Hypersensitivity—Hydroxyurea—psoriasis	0.000194	0.00169	CcSEcCtD
Apixaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000194	0.00453	CbGpPWpGaD
Apixaban—Haemoglobin—Dexamethasone—psoriasis	0.000192	0.00167	CcSEcCtD
Apixaban—Haemoglobin—Betamethasone—psoriasis	0.000192	0.00167	CcSEcCtD
Apixaban—Syncope—Mycophenolate mofetil—psoriasis	0.000192	0.00167	CcSEcCtD
Apixaban—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000192	0.00449	CbGpPWpGaD
Apixaban—Haemorrhage—Dexamethasone—psoriasis	0.000191	0.00166	CcSEcCtD
Apixaban—Haemorrhage—Betamethasone—psoriasis	0.000191	0.00166	CcSEcCtD
Apixaban—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000191	0.00447	CbGpPWpGaD
Apixaban—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000191	0.00166	CcSEcCtD
Apixaban—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000189	0.00442	CbGpPWpGaD
Apixaban—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000188	0.00164	CcSEcCtD
Apixaban—Liver function test abnormal—Methotrexate—psoriasis	0.000186	0.00162	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000185	0.00161	CcSEcCtD
Apixaban—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000184	0.00431	CbGpPWpGaD
Apixaban—Breast disorder—Methotrexate—psoriasis	0.000182	0.00158	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000181	0.00157	CcSEcCtD
Apixaban—Anaphylactic shock—Cyclosporine—psoriasis	0.000179	0.00156	CcSEcCtD
Apixaban—Syncope—Prednisolone—psoriasis	0.000179	0.00156	CcSEcCtD
Apixaban—Eye disorder—Dexamethasone—psoriasis	0.000179	0.00156	CcSEcCtD
Apixaban—Eye disorder—Betamethasone—psoriasis	0.000179	0.00156	CcSEcCtD
Apixaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000178	0.00417	CbGpPWpGaD
Apixaban—Nervous system disorder—Cyclosporine—psoriasis	0.000175	0.00153	CcSEcCtD
Apixaban—Loss of consciousness—Prednisolone—psoriasis	0.000175	0.00153	CcSEcCtD
Apixaban—Thrombocytopenia—Cyclosporine—psoriasis	0.000175	0.00152	CcSEcCtD
Apixaban—Syncope—Hydrocortisone—psoriasis	0.000175	0.00152	CcSEcCtD
Apixaban—Dizziness—Hydroxyurea—psoriasis	0.000174	0.00152	CcSEcCtD
Apixaban—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000174	0.00152	CcSEcCtD
Apixaban—F10—Hemostasis—ITGAL—psoriasis	0.000174	0.00408	CbGpPWpGaD
Apixaban—Skin disorder—Cyclosporine—psoriasis	0.000174	0.00151	CcSEcCtD
Apixaban—Angiopathy—Dexamethasone—psoriasis	0.000173	0.00151	CcSEcCtD
Apixaban—Angiopathy—Betamethasone—psoriasis	0.000173	0.00151	CcSEcCtD
Apixaban—Shock—Mycophenolate mofetil—psoriasis	0.000172	0.00149	CcSEcCtD
Apixaban—Loss of consciousness—Hydrocortisone—psoriasis	0.000171	0.00149	CcSEcCtD
Apixaban—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000171	0.00149	CcSEcCtD
Apixaban—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000171	0.004	CbGpPWpGaD
Apixaban—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000171	0.00149	CcSEcCtD
Apixaban—Skin disorder—Mycophenolate mofetil—psoriasis	0.000169	0.00148	CcSEcCtD
Apixaban—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000169	0.00395	CbGpPWpGaD
Apixaban—Haemoglobin—Prednisone—psoriasis	0.000167	0.00146	CcSEcCtD
Apixaban—Haemorrhage—Prednisone—psoriasis	0.000166	0.00145	CcSEcCtD
Apixaban—Rash—Hydroxyurea—psoriasis	0.000166	0.00145	CcSEcCtD
Apixaban—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000166	0.00389	CbGpPWpGaD
Apixaban—Dermatitis—Hydroxyurea—psoriasis	0.000166	0.00145	CcSEcCtD
Apixaban—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000166	0.00388	CbGpPWpGaD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000165	0.00143	CcSEcCtD
Apixaban—Syncope—Triamcinolone—psoriasis	0.000164	0.00143	CcSEcCtD
Apixaban—Connective tissue disorder—Prednisone—psoriasis	0.000163	0.00142	CcSEcCtD
Apixaban—Hypotension—Mycophenolate mofetil—psoriasis	0.000163	0.00142	CcSEcCtD
Apixaban—Anaphylactic shock—Prednisolone—psoriasis	0.000163	0.00142	CcSEcCtD
Apixaban—Loss of consciousness—Triamcinolone—psoriasis	0.000161	0.0014	CcSEcCtD
Apixaban—Shock—Prednisolone—psoriasis	0.00016	0.00139	CcSEcCtD
Apixaban—Anaphylactic shock—Hydrocortisone—psoriasis	0.000159	0.00138	CcSEcCtD
Apixaban—Nausea—Hydroxyurea—psoriasis	0.000157	0.00137	CcSEcCtD
Apixaban—Shock—Hydrocortisone—psoriasis	0.000156	0.00136	CcSEcCtD
Apixaban—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000156	0.00365	CbGpPWpGaD
Apixaban—Nervous system disorder—Hydrocortisone—psoriasis	0.000156	0.00136	CcSEcCtD
Apixaban—F10—Metabolism of proteins—REN—psoriasis	0.000156	0.00365	CbGpPWpGaD
Apixaban—Eye disorder—Prednisone—psoriasis	0.000155	0.00135	CcSEcCtD
Apixaban—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000155	0.00363	CbGpPWpGaD
Apixaban—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000154	0.00134	CcSEcCtD
Apixaban—Skin disorder—Hydrocortisone—psoriasis	0.000154	0.00134	CcSEcCtD
Apixaban—CYP2J2—Metabolism—NDUFA5—psoriasis	0.000154	0.00361	CbGpPWpGaD
Apixaban—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000154	0.0036	CbGpPWpGaD
Apixaban—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000152	0.00355	CbGpPWpGaD
Apixaban—Angiopathy—Prednisone—psoriasis	0.000151	0.00132	CcSEcCtD
Apixaban—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000151	0.00131	CcSEcCtD
Apixaban—Immune system disorder—Prednisone—psoriasis	0.00015	0.00131	CcSEcCtD
Apixaban—Anaphylactic shock—Triamcinolone—psoriasis	0.00015	0.0013	CcSEcCtD
Apixaban—Syncope—Dexamethasone—psoriasis	0.000149	0.0013	CcSEcCtD
Apixaban—Syncope—Betamethasone—psoriasis	0.000149	0.0013	CcSEcCtD
Apixaban—Hypotension—Hydrocortisone—psoriasis	0.000148	0.00129	CcSEcCtD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000148	0.00348	CbGpPWpGaD
Apixaban—Haematuria—Methotrexate—psoriasis	0.000148	0.00129	CcSEcCtD
Apixaban—Shock—Triamcinolone—psoriasis	0.000147	0.00128	CcSEcCtD
Apixaban—Hepatobiliary disease—Methotrexate—psoriasis	0.000146	0.00128	CcSEcCtD
Apixaban—Loss of consciousness—Betamethasone—psoriasis	0.000146	0.00127	CcSEcCtD
Apixaban—Loss of consciousness—Dexamethasone—psoriasis	0.000146	0.00127	CcSEcCtD
Apixaban—Dizziness—Mycophenolic acid—psoriasis	0.000146	0.00127	CcSEcCtD
Apixaban—Epistaxis—Methotrexate—psoriasis	0.000146	0.00127	CcSEcCtD
Apixaban—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000144	0.00338	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000144	0.00337	CbGpPWpGaD
Apixaban—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000142	0.00333	CbGpPWpGaD
Apixaban—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000142	0.00333	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000142	0.00332	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL13—psoriasis	0.000141	0.0033	CbGpPWpGaD
Apixaban—Haemoglobin—Methotrexate—psoriasis	0.00014	0.00122	CcSEcCtD
Apixaban—Rash—Mycophenolic acid—psoriasis	0.000139	0.00121	CcSEcCtD
Apixaban—Dermatitis—Mycophenolic acid—psoriasis	0.000139	0.00121	CcSEcCtD
Apixaban—Haemorrhage—Methotrexate—psoriasis	0.000139	0.00121	CcSEcCtD
Apixaban—Urinary tract disorder—Methotrexate—psoriasis	0.000137	0.0012	CcSEcCtD
Apixaban—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000137	0.00119	CcSEcCtD
Apixaban—Urethral disorder—Methotrexate—psoriasis	0.000136	0.00119	CcSEcCtD
Apixaban—Anaphylactic shock—Dexamethasone—psoriasis	0.000136	0.00118	CcSEcCtD
Apixaban—Anaphylactic shock—Betamethasone—psoriasis	0.000136	0.00118	CcSEcCtD
Apixaban—Anaemia—Prednisone—psoriasis	0.000134	0.00117	CcSEcCtD
Apixaban—Shock—Dexamethasone—psoriasis	0.000134	0.00116	CcSEcCtD
Apixaban—Shock—Betamethasone—psoriasis	0.000134	0.00116	CcSEcCtD
Apixaban—CYP1A2—Biological oxidations—CYP2S1—psoriasis	0.000133	0.00312	CbGpPWpGaD
Apixaban—Nervous system disorder—Dexamethasone—psoriasis	0.000133	0.00116	CcSEcCtD
Apixaban—Nervous system disorder—Betamethasone—psoriasis	0.000133	0.00116	CcSEcCtD
Apixaban—Thrombocytopenia—Dexamethasone—psoriasis	0.000133	0.00116	CcSEcCtD
Apixaban—Thrombocytopenia—Betamethasone—psoriasis	0.000133	0.00116	CcSEcCtD
Apixaban—Hypersensitivity—Cyclosporine—psoriasis	0.000132	0.00115	CcSEcCtD
Apixaban—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	0.000131	0.00308	CbGpPWpGaD
Apixaban—Nausea—Mycophenolic acid—psoriasis	0.000131	0.00114	CcSEcCtD
Apixaban—CYP2J2—Metabolism—CYP2S1—psoriasis	0.000131	0.00307	CbGpPWpGaD
Apixaban—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	0.000131	0.00307	CbGpPWpGaD
Apixaban—Eye disorder—Methotrexate—psoriasis	0.00013	0.00113	CcSEcCtD
Apixaban—Syncope—Prednisone—psoriasis	0.00013	0.00113	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—IL17A—psoriasis	0.00013	0.00304	CbGpPWpGaD
Apixaban—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	0.000129	0.00303	CbGpPWpGaD
Apixaban—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000128	0.00112	CcSEcCtD
Apixaban—Loss of consciousness—Prednisone—psoriasis	0.000127	0.00111	CcSEcCtD
Apixaban—Hypotension—Dexamethasone—psoriasis	0.000127	0.0011	CcSEcCtD
Apixaban—Hypotension—Betamethasone—psoriasis	0.000127	0.0011	CcSEcCtD
Apixaban—Angiopathy—Methotrexate—psoriasis	0.000126	0.0011	CcSEcCtD
Apixaban—Immune system disorder—Methotrexate—psoriasis	0.000126	0.00109	CcSEcCtD
Apixaban—Mediastinal disorder—Methotrexate—psoriasis	0.000125	0.00109	CcSEcCtD
Apixaban—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000124	0.00291	CbGpPWpGaD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000122	0.00107	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000121	0.00283	CbGpPWpGaD
Apixaban—Hypersensitivity—Prednisolone—psoriasis	0.00012	0.00104	CcSEcCtD
Apixaban—Dizziness—Cyclosporine—psoriasis	0.000118	0.00103	CcSEcCtD
Apixaban—Anaphylactic shock—Prednisone—psoriasis	0.000118	0.00103	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000118	0.00276	CbGpPWpGaD
Apixaban—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000117	0.00102	CcSEcCtD
Apixaban—Gastrointestinal disorder—Betamethasone—psoriasis	0.000117	0.00102	CcSEcCtD
Apixaban—Hypersensitivity—Hydrocortisone—psoriasis	0.000117	0.00102	CcSEcCtD
Apixaban—Shock—Prednisone—psoriasis	0.000116	0.00101	CcSEcCtD
Apixaban—Nervous system disorder—Prednisone—psoriasis	0.000116	0.00101	CcSEcCtD
Apixaban—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000116	0.00272	CbGpPWpGaD
Apixaban—Dizziness—Mycophenolate mofetil—psoriasis	0.000115	0.001	CcSEcCtD
Apixaban—CYP1A2—Tryptophan metabolism—CAT—psoriasis	0.000115	0.00269	CbGpPWpGaD
Apixaban—Skin disorder—Prednisone—psoriasis	0.000115	0.001	CcSEcCtD
Apixaban—Rash—Cyclosporine—psoriasis	0.000113	0.000982	CcSEcCtD
Apixaban—Dermatitis—Cyclosporine—psoriasis	0.000113	0.000981	CcSEcCtD
Apixaban—Anaemia—Methotrexate—psoriasis	0.000112	0.000975	CcSEcCtD
Apixaban—Hypersensitivity—Triamcinolone—psoriasis	0.00011	0.00096	CcSEcCtD
Apixaban—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	0.00011	0.00258	CbGpPWpGaD
Apixaban—Rash—Mycophenolate mofetil—psoriasis	0.00011	0.000958	CcSEcCtD
Apixaban—Dermatitis—Mycophenolate mofetil—psoriasis	0.00011	0.000957	CcSEcCtD
Apixaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00011	0.00257	CbGpPWpGaD
Apixaban—Dizziness—Prednisolone—psoriasis	0.000108	0.000937	CcSEcCtD
Apixaban—Nausea—Cyclosporine—psoriasis	0.000106	0.000925	CcSEcCtD
Apixaban—Dizziness—Hydrocortisone—psoriasis	0.000105	0.000915	CcSEcCtD
Apixaban—Nausea—Mycophenolate mofetil—psoriasis	0.000104	0.000902	CcSEcCtD
Apixaban—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000103	0.00241	CbGpPWpGaD
Apixaban—Rash—Prednisolone—psoriasis	0.000103	0.000894	CcSEcCtD
Apixaban—Dermatitis—Prednisolone—psoriasis	0.000102	0.000893	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000102	0.000892	CcSEcCtD
Apixaban—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000101	0.00237	CbGpPWpGaD
Apixaban—Rash—Hydrocortisone—psoriasis	0.0001	0.000873	CcSEcCtD
Apixaban—Dermatitis—Hydrocortisone—psoriasis	0.0001	0.000872	CcSEcCtD
Apixaban—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.91e-05	0.00232	CbGpPWpGaD
Apixaban—Dizziness—Triamcinolone—psoriasis	9.89e-05	0.000862	CcSEcCtD
Apixaban—Anaphylactic shock—Methotrexate—psoriasis	9.88e-05	0.000861	CcSEcCtD
Apixaban—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	9.86e-05	0.00231	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	9.74e-05	0.00228	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—ACE—psoriasis	9.72e-05	0.00228	CbGpPWpGaD
Apixaban—Nervous system disorder—Methotrexate—psoriasis	9.69e-05	0.000844	CcSEcCtD
Apixaban—Thrombocytopenia—Methotrexate—psoriasis	9.67e-05	0.000843	CcSEcCtD
Apixaban—Nausea—Prednisolone—psoriasis	9.66e-05	0.000842	CcSEcCtD
Apixaban—Skin disorder—Methotrexate—psoriasis	9.6e-05	0.000836	CcSEcCtD
Apixaban—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	9.58e-05	0.00224	CbGpPWpGaD
Apixaban—Nausea—Hydrocortisone—psoriasis	9.44e-05	0.000822	CcSEcCtD
Apixaban—Rash—Triamcinolone—psoriasis	9.43e-05	0.000822	CcSEcCtD
Apixaban—Dermatitis—Triamcinolone—psoriasis	9.42e-05	0.000821	CcSEcCtD
Apixaban—Hypotension—Methotrexate—psoriasis	9.23e-05	0.000804	CcSEcCtD
Apixaban—Dizziness—Dexamethasone—psoriasis	8.98e-05	0.000782	CcSEcCtD
Apixaban—Dizziness—Betamethasone—psoriasis	8.98e-05	0.000782	CcSEcCtD
Apixaban—Nausea—Triamcinolone—psoriasis	8.89e-05	0.000774	CcSEcCtD
Apixaban—CYP3A4—Tryptophan metabolism—CAT—psoriasis	8.87e-05	0.00208	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IL10—psoriasis	8.82e-05	0.00207	CbGpPWpGaD
Apixaban—Hypersensitivity—Prednisone—psoriasis	8.71e-05	0.000759	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—IL4—psoriasis	8.58e-05	0.00201	CbGpPWpGaD
Apixaban—Rash—Dexamethasone—psoriasis	8.56e-05	0.000746	CcSEcCtD
Apixaban—Rash—Betamethasone—psoriasis	8.56e-05	0.000746	CcSEcCtD
Apixaban—Dermatitis—Dexamethasone—psoriasis	8.55e-05	0.000745	CcSEcCtD
Apixaban—Dermatitis—Betamethasone—psoriasis	8.55e-05	0.000745	CcSEcCtD
Apixaban—Gastrointestinal disorder—Methotrexate—psoriasis	8.53e-05	0.000743	CcSEcCtD
Apixaban—ABCB1—Allograft Rejection—HLA-B—psoriasis	8.39e-05	0.00197	CbGpPWpGaD
Apixaban—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	8.38e-05	0.00196	CbGpPWpGaD
Apixaban—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	8.37e-05	0.00196	CbGpPWpGaD
Apixaban—Nausea—Betamethasone—psoriasis	8.06e-05	0.000702	CcSEcCtD
Apixaban—Nausea—Dexamethasone—psoriasis	8.06e-05	0.000702	CcSEcCtD
Apixaban—Dizziness—Prednisone—psoriasis	7.82e-05	0.000681	CcSEcCtD
Apixaban—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.81e-05	0.00183	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-A—psoriasis	7.77e-05	0.00182	CbGpPWpGaD
Apixaban—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	7.68e-05	0.0018	CbGpPWpGaD
Apixaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.64e-05	0.00179	CbGpPWpGaD
Apixaban—Rash—Prednisone—psoriasis	7.45e-05	0.000649	CcSEcCtD
Apixaban—Dermatitis—Prednisone—psoriasis	7.45e-05	0.000649	CcSEcCtD
Apixaban—Hypersensitivity—Methotrexate—psoriasis	7.28e-05	0.000634	CcSEcCtD
Apixaban—F10—Hemostasis—NOS2—psoriasis	7.15e-05	0.00167	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	7.1e-05	0.00166	CbGpPWpGaD
Apixaban—Nausea—Prednisone—psoriasis	7.02e-05	0.000612	CcSEcCtD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.88e-05	0.00161	CbGpPWpGaD
Apixaban—Dizziness—Methotrexate—psoriasis	6.53e-05	0.000569	CcSEcCtD
Apixaban—CYP2J2—Metabolism—CARM1—psoriasis	6.41e-05	0.0015	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.38e-05	0.00149	CbGpPWpGaD
Apixaban—Rash—Methotrexate—psoriasis	6.23e-05	0.000543	CcSEcCtD
Apixaban—Dermatitis—Methotrexate—psoriasis	6.22e-05	0.000542	CcSEcCtD
Apixaban—ABCG2—Metabolism—NDUFA5—psoriasis	6.21e-05	0.00145	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—LEP—psoriasis	6.04e-05	0.00141	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.99e-05	0.0014	CbGpPWpGaD
Apixaban—Nausea—Methotrexate—psoriasis	5.87e-05	0.000511	CcSEcCtD
Apixaban—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	5.77e-05	0.00135	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.52e-05	0.00129	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	5.5e-05	0.00129	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.31e-05	0.00124	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CYP2S1—psoriasis	5.28e-05	0.00124	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—IFNG—psoriasis	5.19e-05	0.00121	CbGpPWpGaD
Apixaban—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	5.18e-05	0.00121	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.82e-05	0.00113	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.82e-05	0.00113	CbGpPWpGaD
Apixaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.52e-05	0.00106	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—NDUFA5—psoriasis	4.45e-05	0.00104	CbGpPWpGaD
Apixaban—F10—Hemostasis—VEGFA—psoriasis	4.14e-05	0.00097	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.13e-05	0.000968	CbGpPWpGaD
Apixaban—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.13e-05	0.000968	CbGpPWpGaD
Apixaban—F10—Metabolism of proteins—CXCL8—psoriasis	4.01e-05	0.000939	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.97e-05	0.00093	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—CAT—psoriasis	3.94e-05	0.000923	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.92e-05	0.000917	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—NDUFA5—psoriasis	3.85e-05	0.000902	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CYP2S1—psoriasis	3.78e-05	0.000886	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.59e-05	0.000841	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NDUFA5—psoriasis	3.44e-05	0.000805	CbGpPWpGaD
Apixaban—ABCB1—Allograft Rejection—TNF—psoriasis	3.36e-05	0.000786	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NDUFA5—psoriasis	3.36e-05	0.000786	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.34e-05	0.000782	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CYP2S1—psoriasis	3.28e-05	0.000767	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.21e-05	0.000751	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NDUFA5—psoriasis	3.14e-05	0.000734	CbGpPWpGaD
Apixaban—F10—Hemostasis—TP53—psoriasis	3.13e-05	0.000733	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.12e-05	0.000731	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—APOE—psoriasis	3.06e-05	0.000717	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.98e-05	0.000697	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP2S1—psoriasis	2.92e-05	0.000685	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.92e-05	0.000685	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP2S1—psoriasis	2.85e-05	0.000668	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NDUFA5—psoriasis	2.68e-05	0.000628	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—PPARG—psoriasis	2.67e-05	0.000625	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP2S1—psoriasis	2.67e-05	0.000624	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CARM1—psoriasis	2.58e-05	0.000604	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.5e-05	0.000585	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP2S1—psoriasis	2.28e-05	0.000534	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.21e-05	0.000518	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.13e-05	0.000499	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NDUFA5—psoriasis	2.07e-05	0.000484	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.93e-05	0.000453	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CARM1—psoriasis	1.85e-05	0.000433	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP2S1—psoriasis	1.76e-05	0.000412	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.72e-05	0.000402	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.66e-05	0.000388	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CARM1—psoriasis	1.6e-05	0.000375	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CAT—psoriasis	1.59e-05	0.000371	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.53e-05	0.000359	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.5e-05	0.00035	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.46e-05	0.000342	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CARM1—psoriasis	1.43e-05	0.000334	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.4e-05	0.000327	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CARM1—psoriasis	1.39e-05	0.000326	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.33e-05	0.000313	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CARM1—psoriasis	1.3e-05	0.000305	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—APOE—psoriasis	1.23e-05	0.000289	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.22e-05	0.000285	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.19e-05	0.00028	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CAT—psoriasis	1.14e-05	0.000266	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CARM1—psoriasis	1.11e-05	0.000261	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PPARG—psoriasis	1.07e-05	0.000251	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000244	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CAT—psoriasis	9.84e-06	0.00023	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—APOE—psoriasis	8.83e-06	0.000207	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CAT—psoriasis	8.78e-06	0.000206	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CARM1—psoriasis	8.59e-06	0.000201	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CAT—psoriasis	8.57e-06	0.000201	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CAT—psoriasis	8.01e-06	0.000188	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PPARG—psoriasis	7.69e-06	0.00018	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—APOE—psoriasis	7.64e-06	0.000179	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CAT—psoriasis	6.84e-06	0.00016	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—APOE—psoriasis	6.82e-06	0.00016	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—APOE—psoriasis	6.66e-06	0.000156	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PPARG—psoriasis	6.66e-06	0.000156	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—APOE—psoriasis	6.22e-06	0.000146	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PPARG—psoriasis	5.94e-06	0.000139	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PPARG—psoriasis	5.8e-06	0.000136	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PPARG—psoriasis	5.42e-06	0.000127	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—APOE—psoriasis	5.32e-06	0.000125	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CAT—psoriasis	5.28e-06	0.000124	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PPARG—psoriasis	4.63e-06	0.000108	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—APOE—psoriasis	4.1e-06	9.61e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PPARG—psoriasis	3.57e-06	8.37e-05	CbGpPWpGaD
